Table 1 Clinico-pathological features of patients at time of MOC administration
All cases (N = 54) | |
|---|---|
Age at diagnosis of recurrence, yrs | |
Median (range) | 69 (40–89) |
ECOG PS | |
0 | 20 (37.0) |
1 | 18 (33.3) |
2 | 16 (29.6) |
Platinum sensitivity | |
Refractory/resistant | 20 (37.0) |
Sensitive | 34 (63.0) |
No. prior regimens | |
1-2 | 11 (20.4) |
3-4 | 23 (42.6) |
5-6 | 16 (29.6) |
≥7 | 4 ( 7.4) |
Previous anthracyclines | |
No | 14 (25.9) |
Yes | 40 (74.1) |
Pattern of recurrence | |
Carcinomatosis only | 9 (16.7) |
Carcinomatosis and parenchymal metastasis | 8 (14.8) |
Carcinomatosis and lymph node disease | 14 (25.9) |
Carcinomatosis, parenchymal metastases and lymph node disease | 12 (22.2) |
Isolated parenchymal metastases or lymph node disease | 11 (20.4) |
Ca125 levels (IU/ml) at baseline | |
Median (range) | 508 (10–9,500) |
≤35 I.U./ml | 3 ( 5.6) |
>35 I.U./ml | 51 (94.4) |